157 related articles for article (PubMed ID: 7214106)
21. Stability of serum neuroleptic and prolactin concentrations during short- and long-term treatment of schizophrenic patients.
Rao ML; Brown WA
Psychopharmacology (Berl); 1987; 93(2):237-42. PubMed ID: 2892222
[TBL] [Abstract][Full Text] [Related]
22. [The effect of propranolol, neuroleptics and their combination on serum prolactin levels of schizophrenic patients].
Elizur A; Segal Z; Yeret A; Aboo-Shach M; Ben-David M
Harefuah; 1979 Sep; 97(5-6):101-4. PubMed ID: 44254
[No Abstract] [Full Text] [Related]
23. Sulpiride and haloperidol in schizophrenia: a double-blind cross-over study of therapeutic effect, side effects and plasma concentrations.
Gerlach J; Behnke K; Heltberg J; Munk-Anderson E; Nielsen H
Br J Psychiatry; 1985 Sep; 147():283-8. PubMed ID: 3904885
[TBL] [Abstract][Full Text] [Related]
24. Orphenadrine plasma levels and amelioration of extrapyramidal side effects in schizophrenic patients treated with haloperidol.
Altamura AC; Buccio M; Colacurcio F; Colombo G; Terzi A
Acta Neurol (Napoli); 1986 Feb; 8(1):19-26. PubMed ID: 3962752
[No Abstract] [Full Text] [Related]
25. Haloperidol plasma level after a test dose as predictor for the clinical response to treatment in acute schizophrenic patients.
Louza Neto MR; Müller-Spahn F; Rüther E; Scherer J
Pharmacopsychiatry; 1988 Sep; 21(5):226-31. PubMed ID: 3227054
[TBL] [Abstract][Full Text] [Related]
26. Suspension therapy in acute schizophrenia. Clinical and neuroendocrine/biochemical effects of abrupt discontinuation of neuroleptic medication.
Kuhs H; Folkerts H
Neuropsychobiology; 1995; 31(3):135-45. PubMed ID: 7609862
[TBL] [Abstract][Full Text] [Related]
27. Haloperidol and reduced haloperidol plasma levels in Chinese vs. non-Chinese psychiatric patients.
Jann MW; Chang WH; Davis CM; Chen TY; Deng HC; Lung FW; Ereshefsky L; Saklad SR; Richards AL
Psychiatry Res; 1989 Oct; 30(1):45-52. PubMed ID: 2594870
[TBL] [Abstract][Full Text] [Related]
28. Cyproheptadine augmentation of haloperidol in chronic schizophrenic patients: a double-blind placebo-controlled study.
Lee HS; Song DH; Kim JH; Lee YM; Han ES; Yoo KJ
Int Clin Psychopharmacol; 1995 Jun; 10(2):67-72. PubMed ID: 7673658
[TBL] [Abstract][Full Text] [Related]
29. Combination therapy with haloperidol and orphenadrine in schizophrenia. A clinical and pharmacokinetic study.
Altamura AC; Buccio M; Colombo G; Terzi A; Cazzullo CL
Encephale; 1986; 12(1):31-6. PubMed ID: 3698889
[TBL] [Abstract][Full Text] [Related]
30. Haloperidol and reduced haloperidol plasma levels in selected schizophrenic patients.
Ereshefsky L; Davis CM; Harrington CA; Jann MW; Browning JL; Saklad SR; Burch NR
J Clin Psychopharmacol; 1984 Jun; 4(3):138-42. PubMed ID: 6736273
[TBL] [Abstract][Full Text] [Related]
31. Advantages and disadvantages of depot-neuroleptics as maintenance medication for chronic schizophrenics.
Möller HJ; Kissling W
Clin Neuropharmacol; 1986; 9 Suppl 4():259-62. PubMed ID: 2882841
[No Abstract] [Full Text] [Related]
32. [Use of haloperidol in high doses in schizophrenia. Clinical, biochemical and pharmacokinetic study].
Scatton B; Zarifian E; Bianchetti G; Cuche H; Loo H; Morselli PL
Encephale; 1982; 8(1):1-8. PubMed ID: 7094868
[TBL] [Abstract][Full Text] [Related]
33. Plasma catecholamine metabolites and early response to haloperidol.
Bowers MB; Swigar ME; Jatlow PI; Goicoechea N
J Clin Psychiatry; 1984 Jun; 45(6):248-51. PubMed ID: 6725216
[TBL] [Abstract][Full Text] [Related]
34. Neuroendocrine effects of haloperidol decanoate in patients with chronic schizophrenia.
Meco G; Falaschi P; Casacchia M; Rocco A; Petrini P; Rosa M; Agnoli A
Adv Biochem Psychopharmacol; 1985; 40():89-93. PubMed ID: 4025041
[No Abstract] [Full Text] [Related]
35. High doses of haloperidol in schizophrenia. A clinical, biochemical, and pharmacokinetic study.
Zarifian E; Scatton B; Bianchetti G; Cuche H; Loo H; Morselli PL
Arch Gen Psychiatry; 1982 Feb; 39(2):212-5. PubMed ID: 7065833
[TBL] [Abstract][Full Text] [Related]
36. Prolactin response to single and multiple doses of haloperidol in schizophrenic patients.
Ravichandran GK; Lu RB; Shvartsburd A; Misra CH; Ho BT; Kahn M; Smith RC
Psychiatry Res; 1984 Jan; 11(1):61-9. PubMed ID: 6584932
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics of haloperidol and fluphenazine decanoates in chronic schizophrenia.
Wiles DH; McCreadie RG; Whitehead A
Psychopharmacology (Berl); 1990; 101(2):274-81. PubMed ID: 2349370
[TBL] [Abstract][Full Text] [Related]
38. Plasma haloperidol levels drawn at neuroleptic threshold doses: a pilot study.
McEvoy JP; Stiller RL; Farr R
J Clin Psychopharmacol; 1986 Jun; 6(3):133-8. PubMed ID: 3711363
[TBL] [Abstract][Full Text] [Related]
39. Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine.
Alfaro CL; Wudarsky M; Nicolson R; Gochman P; Sporn A; Lenane M; Rapoport JL
J Child Adolesc Psychopharmacol; 2002; 12(2):83-91. PubMed ID: 12188977
[TBL] [Abstract][Full Text] [Related]
40. Correlation between plasma levels of prolactin and chlorpromazine in psychiatric patients.
Kolakowska T; Wiles DH; McNeilly AS; Gelder MG
Psychol Med; 1975 May; 5(2):214-6. PubMed ID: 240179
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
